<html lang="en"><meta name="viewport" content="width=device-width, initial-scale=1" /><head><!-- Global site tag (gtag.js) - Google Analytics --><script async src="https://www.googletagmanager.com/gtag/js?id=G-2VYEP6CXDE"></script><script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag("js", new Date());  gtag("config", "G-2VYEP6CXDE");</script><link rel="stylesheet" href="../init.css"><title>What is COVAX?</title></head><body><div class="ds-layout-grid ds-layout-grid--edged layout-article-header"><div class="article__lead-image" data-test-id="Lead Image"><div itemprop="image" itemscope="" itemtype="https://schema.org/ImageObject"><meta content="https://www.economist.com/img/b/1280/720/90/sites/default/files/20210227_BLP511.jpg" itemprop="url"/><img alt="" height="720" sizes="(min-width: 1440px) 940px, (min-width: 1080px) 75vw, (min-width: 960px) 90vw, (min-width: 800px) 720px, 95vw" src="../image/20210227_BLP511.jpg" srcset="../image/20210227_BLP511.jpg" width="1280"/></div></div><header class="article__header"><h1><span class="article__subheadline" data-test-id="Article Subheadline">The Economist explains</span><br/><span class="article__headline" data-test-id="Article Headline" itemprop="headline">What is COVAX?</span></h1><h2 class="article__description" data-test-id="Article Description" itemprop="description">The vaccine-sharing scheme is designed to help poor countries compete in the vaccination race</h2></header><script type="application/ld+json">
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.economist.com/the-economist-explains/","name":"The Economist explains"}}]}
</script><div class="article__section" data-test-id="Blog Identity"><strong><span class="article__section-subheadline" data-test-id="Blog Section Subheadline">Explaining the world, daily</span><br/><span class="article__section-headline" id="blogsiteheadline"><a data-test-id="Blog Section Headline" href="/the-economist-explains/">The Economist explains</a></span></strong></div><hr class="ds-rule layout-article-header__rule"/><div class="advert right hidden advert--right-rail" id=""><div><div id="econright-r0"></div></div></div></div><div class="ds-layout-grid ds-layout-grid--edged layout-article-body" itemprop="text"><div class="layout-sticky-rail"><div class="layout-sticky-rail-advert-wrapper"><div class="advert right hidden advert--right-rail advert--sticky-rail" id=""><div><div id="econright-r1"></div></div></div></div></div><p class="article__body-text">MORE THAN 200m doses of covid-19 vaccines have been administered around the world since December, when Britain approved the first <a href="./britains-vaccination-campaign-begins-to-show-results.html">rigorously tested jabs</a> for mass vaccination. But as rich countries have rushed to inoculate their populations, poorer ones have watched from the sidelines. Only a handful of African countries have been able to afford vaccines, and many lack enough “cold chain” capacity to store them. Vaccine hoarding is also to blame for the unequal roll-out of the jabs. <a href="https://www.economist.com/graphic-detail/2021/02/13/there-will-be-enough-vaccines-for-all-if-rich-countries-share">The 54 wealthiest countries are home to 18% of the world’s adult population, but have ordered 40% of all available vaccines</a>. Covid-19 vaccines Global Access Facility (COVAX), a vaccine-sharing scheme, offers a partial solution to the problems this will create. On February 24th Ghana became the first country in the world to receive jabs under the scheme. So what is COVAX?</p><style data-emotion="css bvf2nr">.css-bvf2nr{padding-bottom:1.5rem;margin:1.3125rem 0 2.1875rem;padding:0;}</style><div class="layout-article-promo inline-newsletter-promo css-bvf2nr eq1ndt50"><style data-emotion="css 10eieub">.css-10eieub{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background:var(--ds-color-los-angeles-95);border:0.0625rem solid var(--ds-color-los-angeles-85);border-radius:0.125rem;color:var(--ds-color-london-5);display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;font-family:var(--ds-type-system-sans);line-height:var(--ds-type-leading-lower);padding:0 var(--ds-grid-gutter) 1.5rem var(--ds-grid-gutter);text-align:center;}.css-10eieub ._content-promo-subheadline,.css-10eieub ._content-promo-tagline,.css-10eieub ._content-promo-tagline-separator{font-size:var(--ds-type-scale--3);font-weight:500;letter-spacing:0.03rem;margin-bottom:0.125rem;text-transform:uppercase;}.css-10eieub ._content-promo-tagline{color:var(--ds-color-economist-red);}.css-10eieub ._content-promo-headline{font-family:var(--ds-type-system-serif);font-size:var(--ds-type-scale-4);font-weight:700;line-height:var(--ds-type-leading-upper);}.css-10eieub ._content-promo-description{font-size:var(--ds-type-scale-0);font-weight:400;}.css-10eieub *+._content-promo-description{margin-top:0.25rem;}.css-10eieub ._content-promo-ident{-webkit-align-self:center;-ms-flex-item-align:center;align-self:center;}.css-10eieub *+._content-promo-cta{margin-top:1.5rem;}.css-10eieub ._ds-ident{display:block;padding:1rem;}@media (min-width: 37.5rem){.css-10eieub{-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;padding:0.5rem 1.5rem 1.25rem 0.375rem;text-align:initial;}.css-10eieub ._content-promo-ident{-webkit-align-self:flex-start;-ms-flex-item-align:flex-start;align-self:flex-start;}.css-10eieub ._content-promo-headline{margin-top:1rem;}.css-10eieub ._content-promo-subheadline-container{margin-top:1rem;}.css-10eieub *+._content-promo-headline{margin-top:0;}.css-10eieub ._content-promo-content{margin:0 0 0 1rem;}}</style><div class="_newsletterContentPromo css-10eieub e1pgax3g0"><div class="_content-promo-ident"><span class="ds-ident-newsletters ds-ident-newsletters--the-economist-today _ds-ident"><svg class="ds-ident-newsletters__svg" height="120" viewbox="0 0 112 112" width="120" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><circle cx="55.95" cy="56" id="prefix__a" r="55.944"></circle></defs><g fill="none" fill-rule="evenodd"><mask fill="#fff" id="prefix__b"><use xlink:href="#prefix__a"></use></mask><use fill="#2E45B8" xlink:href="#prefix__a"></use><path d="M55.907 23.329c18.322 0 33.175 15.003 33.175 33.51 0 18.508-14.853 33.51-33.175 33.51-18.322 0-33.175-15.002-33.175-33.51 0-18.507 14.853-33.51 33.175-33.51z" fill="#2F44B8" mask="url(#prefix__b)"></path><path d="M35.757 83.077c-7.92-6.094-13.025-15.684-13.025-26.47 0-4.191.768-8.213 2.175-11.908L55.85 56.822 35.757 82.976" fill="#CED3F3" mask="url(#prefix__b)"></path><path d="M76.103 83.46c-5.588 4.322-12.716 6.89-20.293 6.89-7.597 0-14.832-2.547-20.427-6.89l20.448-26.565L76.103 83.46z" fill="#ADB6EB" mask="url(#prefix__b)"></path><path d="M55.851 56.895V23.217c14.296 0 26.563 9.42 31.193 22.336L55.85 56.895z" fill="#6D7BDA" mask="url(#prefix__b)"></path><path d="M87.246 45.37L55.851 56.949 76.02 83.413c7.97-6.085 13.175-15.672 13.175-26.465 0-4.008-.648-7.85-1.948-11.409v-.168z" fill="#8D98E2" mask="url(#prefix__b)"></path><path d="M55.851 57.455l-.003-34.014c-14.167 0-26.218 9.02-30.99 21.615 7.086 2.762 17.417 6.895 30.993 12.399z" fill="#EBEDFA" mask="url(#prefix__b)"></path><path d="M46.005 21.538h19.692v-6.377H46.005z" fill="#FFF" mask="url(#prefix__b)"></path><path d="M57.459 45.968l6.635.048.152 20.962-6.636-.048z" fill="#0D0D0D" mask="url(#prefix__b)" transform="rotate(45 60.852 56.473)"></path><path d="M47.553 46.016l6.635-.048-.151 20.962-6.636.048z" fill="#0D0D0D" mask="url(#prefix__b)" transform="rotate(135 50.795 56.473)"></path><path d="M55.963 87.582c-16.756 0-30.308-13.696-30.308-30.631 0-16.935 13.552-30.632 30.308-30.632s30.308 13.697 30.308 30.632c0 16.935-13.552 30.631-30.308 30.631m34.786-56.526l-4.591-4.596-4.248 4.343a36.857 36.857 0 00-5.835-4.835c-5.801-3.862-12.7-6.108-20.112-6.108-20.266 0-36.7 16.609-36.7 37.091s16.393 37.091 36.7 37.091c20.307 0 36.7-16.609 36.7-37.091 0-7.85-2.444-15.129-6.576-21.13l4.662-4.765z" fill="#FFF" mask="url(#prefix__b)"></path></g></svg></span></div><div class="_content-promo-content"><div class="_content-promo-subheadline-container"><span class="_content-promo-subheadline">The Economist Today</span></div><h2 class="_content-promo-headline">Hand-picked stories, in your inbox</h2><div class="_content-promo-description"><p>A daily email with the best of our journalism</p></div><div class="_content-promo-cta"><style data-emotion="css 1ab4byb">.css-1ab4byb .ds-form-label{display:none;}.css-1ab4byb .ds-form-notice{margin-top:1rem;}@media (min-width: 37.5rem){.css-1ab4byb .ds-form-field-combined-input{max-width:28rem;}}</style><div class="css-1ab4byb e12hvj4w0"><div class=""><label class="ds-form-label" for=""><span></span></label><div class="ds-form-field-combined-input"><input class="ds-form-input" id="" maxlength="320" name="" placeholder="example@email.com" type="email" value=""/><button class="ds-button">Sign up</button></div></div></div></div></div></div></div><p class="article__body-text">When vaccine-makers unveiled their covid-19 candidates, governments raced to secure supplies. A recent analysis by ONE Campaign, an advocacy group, shows that rich countries have stockpiled over 1bn doses more than they need. This evoked something of a sense of déjà vu. In 2009 an outbreak of swine flu (known as A/H1N1) killed nearly 285,000 people worldwide. Vaccines were developed within months, and first became available in high-income countries where most doses had been secured through bilateral agreements with drug firms. After shortages and production delays, developing countries found themselves pushed to the back of the queue. By the time jabs were available for them, three months later, the epidemic had peaked and the vaccines were less useful.</p><div class="advert incontent hidden advert--inline" id=""><div><div id="econ-1"></div></div></div><p class="article__body-text">COVAX was established to prevent a repeat. One of the scheme’s motivations is humanitarian. Another is to hinder the emergence of new variants resistant to the vaccines (the more widely a virus spreads, <a href="./when-covid-19-vaccines-meet-the-new-variants-of-the-virus.html">the more likely it is to mutate</a>). It is led by the World Health Organisation, Gavi (a public-private vaccine-promoting alliance) and the Coalition for Epidemic Preparedness Innovations (a foundation that finances research into vaccines for pandemics), and aims to ensure that all participating countries have access to inoculations. All countries in Africa have signed up to the scheme, which now has 190 members. Of these, 92 fall into the low- and middle-income group. </p><p class="article__body-text">Success hinges on international support. COVAX operates through a funding mechanism that gives richer countries a choice. They can pay for their jabs and those of countries unable to afford any, or—if they have already met their own needs through bilateral deals—they can pay only for the doses of poorer countries. The good news is that more countries are stepping up their contributions. Last week leaders of the G7, a club of advanced economies, pledged $4.3bn in new funding, bringing the total amount committed so far to $10.3bn. The scheme is just $800m short of this year’s target. </p><p class="article__body-text">The jabs, mostly supplied by AstraZeneca/Oxford, are allocated according to countries’ populations. The facility plans to supply enough vaccines for 3% of the participating countries’ people by the summer, which would protect health-care workers. By the end of the year it intends to have delivered 2bn doses, enough for 20% of their populations.</p><p class="article__body-text">Hurdles loom. First, the logistics are unnerving. The UN Children’s Fund, UNICEF, which will take the leading role in delivering vaccines, is preparing to distribute up to 850 tonnes of jabs per month, or more than double the average weight of vaccines it usually transports. Second, the number of doses allocated to each country is likely to be limited by persistent global shortages (some producers have already fallen behind schedule). And third, countries’ preparedness matters. Gavi says COVAX will not deliver doses to those that cannot store and distribute them. Even so, developing countries may not be able to achieve widespread vaccination until mid-2023 or early 2024, if ever. </p><p class="article__body-text"><em>For more on the race between injections and infections, listen to <a href="./the-jab-how-well-will-vaccines-work.html">The Jab</a>, our podcast on the global vaccination effort. And find more of our coverage of the pandemic at <a href="./coronavirus-pandemic.html">economist.com/coronavirus</a></em></p><div class="layout-article-links layout-article-promo"><a class="ds-actioned-link ds-actioned-link--reuse-this-content" href="https://s100.copyright.com/AppDispatchServlet?publisherName=economist&amp;publication=economist&amp;title=What%20is%20COVAX%3F&amp;publicationDate=2021-02-24&amp;contentID=%2Fcontent%2F71im7lf6gt6dfc6kiem0k04h1344o6fd&amp;type=A&amp;orderBeanReset=TRUE" target="_blank"><span>Reuse this content</span></a><a class="ds-actioned-link ds-actioned-link--the-trust-project" href="https://www.economist.com/about-the-economist"><span>The Trust Project</span></a></div></div></body></html>